Search | Clinical Trials Finder

Conditions: Aging
Interventions: Vitamin D3 (cholecalciferol), fish oil; Dietary Supplement · Drug
Lead sponsor: Augusta University; Other
Eligibility: 50 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Healthy
Interventions: Recom Model 100, GE 5000 ECG Monitor System; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Cardiac Electrical Function
Interventions: 12 Lead Glove; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Ischemic
Interventions: wearable wristband model, Samsung Galaxy Watch 6, Standard of care extended ECG monitoring; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 55 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions: COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting; Device · Other
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Pasadena, California • Nashville, Tennessee

Conditions: Epilepsy
Interventions: Accelerometer Device; Device
Lead sponsor: Cyberonics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Gainesville, Florida • Chicago, Illinois

Conditions: Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
Interventions: AK+ Guard™ ECG Application; Device
Lead sponsor: AccurKardia, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Hypertension, Sleep Disorder, Healthy
Interventions: 24 hour blood pressure (BP) monitoring, Polysomnography; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma
Interventions: Mobile Cardiac Telemetry, Wearable Cardiac Monitor; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Tachycardia, Sudden Cardiac Death
Interventions: ECG, Echocardiography, Cardiac MRI, Ambulatory ECG recording, Cardiac EP study, All study subjects will undergo sample collection for genetic testing.; Diagnostic Test · Genetic
Lead sponsor: Sheri Kashmir Institute of Medical Sciences; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Zio XT® Patch; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 24,060 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions: SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H; Device
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Aortic Stenosis, Diastolic Dysfunction
Interventions: AI-ECG Dashboard, Point of care ultrasound (POCUS); Device · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure, Chronic Kidney Diseases
Interventions: CorBand, Activity Monitor, Bioimpedance spectrometer, ECG, respiratory rate sensor; Device · Other
Lead sponsor: ReThink Medical; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: San Francisco, California • San Jose, California

Conditions: Sarcoidosis, Cardiac Sarcoidosis, Boeck's Disease, Besnier-Boeck Disease
Interventions: Enhanced Screening Protocol for Cardiac Sarcoidosis., Routine Screening for Suspected Cardiac Sarcoidosis; Diagnostic Test
Lead sponsor: Foundation for Sarcoidosis Research; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Denver, Colorado • Chicago, Illinois • Iowa City, Iowa + 6 more

Conditions: Atrial Fibrillation
Interventions: Single lead ambulatory ECG patch; Diagnostic Test
Lead sponsor: Fitbit LLC; Industry
Eligibility: 22 Years and older
Enrollment: 450,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Arrhythmias, Cardiac, Heart Block
Interventions: Holter Monitor, Zio Patch; Device
Lead sponsor: Columbia University; Other
Eligibility: Up to 21 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
Interventions: Belzutifan; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation (AF)
Interventions: Kardia Mobile 6L Device; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperkalemia
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 89 Years
Enrollment: 1,151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiomyopathy
Interventions: KardiaRx ECG Screening and AI interpretation of ECG; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Malignant Digestive System Neoplasm
Interventions: Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration; Procedure · Drug · Device + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Syncope, Pre-syncope, Atrial Fibrillation, Supraventricular Tachycardia
Interventions: Standard Holter/Investigational patch; Device
Lead sponsor: Seattle Institute for Cardiac Research; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Enumclaw, Washington

Search by objective public record fields.

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG

A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function

DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

3-Dimensional Accelerometer Sub-Study

AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

Study of Disrupted Sleep in Somali Americans

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

South Asian Arrhythmogenic Cardiomyopathy Registry

The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

AI in Outpatient Practice for Diagnosing Aortic Stenosis and Diastolic Dysfunction

A Study AnalyZing a NovEl Wearable SeNsor for Remote PatIent Health Monitoring

Routine Cardiac Screening in Sarcoidosis Patients

Validation of Software for Assessment of Atrial Fibrillation From PPG Data Acquired by a Wearable Smartwatch

Holter Versus Zio Patch Electrocardiographic Monitoring in Children

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation

A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)

AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

The Simple ECG Monitoring Trial (Comparison of a Novel Recording System With a Standard Holter Monitor)